Pro Medicus (PME.AX) Stock Price

Pro Medicus Price

ASX·CLOSED
198.85AUD+2.10 (+1.06 %)
Market closed

Revenue has compounded at 16.6% per year over the past 19 years to 220.54 M AUD. Earnings per share have grown at 16.5% per year over the last 19 years. Pro Medicus's net margin stands at 52.2%, up from 45.3% several years earlier. Pro Medicus currently offers a dividend yield of about 0.40%. The payout ratio is around 71% of earnings. The dividend has grown at 20.9% per year over the past 19 years. Analysts set a median price target of 244.80 AUD, implying 23.1% above the current price. Of 17 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 84% above its 52-week low.

Pro Medicus stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pro Medicus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pro Medicus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pro Medicus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pro Medicus Stock Price History
DatePro Medicus Price
8/19/2026198.85 AUD
8/18/2026196.75 AUD
8/17/2026175.67 AUD
8/14/2026178.86 AUD
8/13/2026183.71 AUD
8/12/2026181.67 AUD
8/11/2026182.21 AUD
8/10/2026175.28 AUD
8/7/2026176.08 AUD
8/6/2026177.54 AUD
8/5/2026180.14 AUD
8/4/2026172.82 AUD
8/3/2026164.45 AUD
7/31/2026162.21 AUD
7/30/2026160.70 AUD
7/29/2026163.94 AUD
7/28/2026163.14 AUD
7/27/2026160.69 AUD
7/24/2026159.82 AUD
7/23/2026162.13 AUD
7/22/2026173.45 AUD
7/21/2026180.04 AUD
7/20/2026188.79 AUD
7/17/2026187.11 AUD
7/16/2026193.81 AUD
7/15/2026193.41 AUD
7/14/2026191.24 AUD
7/13/2026197.86 AUD
7/10/2026198.36 AUD
7/9/2026210.42 AUD
7/8/2026212.13 AUD
7/7/2026210.74 AUD
7/6/2026213.77 AUD
7/3/2026211.03 AUD
7/2/2026205.24 AUD
7/1/2026206.47 AUD
6/30/2026200.87 AUD
6/29/2026194.61 AUD
6/26/2026188.49 AUD
6/25/2026184.28 AUD
6/24/2026180.18 AUD
6/23/2026172.93 AUD
6/22/2026174.64 AUD
6/19/2026167.14 AUD
6/18/2026168.92 AUD
6/17/2026166.06 AUD
6/16/2026164.18 AUD
6/15/2026163.32 AUD
6/12/2026163.96 AUD
6/11/2026162.22 AUD
6/10/2026161.58 AUD
6/9/2026165.79 AUD
6/5/2026165.70 AUD
6/4/2026161.37 AUD
6/3/2026159.30 AUD
6/2/2026160.08 AUD
6/1/2026143.28 AUD
5/29/2026130.67 AUD
5/28/2026129.95 AUD
5/27/2026131.59 AUD
5/26/2026126.28 AUD
5/25/2026126.21 AUD
5/22/2026127.17 AUD
5/21/2026129.79 AUD
5/20/2026127.98 AUD
5/19/2026130.26 AUD
5/18/2026125.52 AUD
5/15/2026122.11 AUD
5/14/2026121.60 AUD
5/13/2026125.50 AUD
5/12/2026125.93 AUD
5/11/2026129.60 AUD
5/8/2026129.49 AUD
5/7/2026129.92 AUD
5/6/2026132.79 AUD
5/5/2026136.28 AUD
5/4/2026138.67 AUD
5/1/2026136.16 AUD
4/30/2026134.40 AUD
4/29/2026134.84 AUD
4/28/2026136.00 AUD
4/27/2026138.12 AUD
4/24/2026138.34 AUD
4/23/2026141.63 AUD
4/22/2026140.58 AUD
4/21/2026142.23 AUD
4/20/2026144.80 AUD
4/17/2026148.74 AUD
4/16/2026148.88 AUD
4/15/2026137.42 AUD
4/14/2026132.02 AUD
4/13/2026132.38 AUD
4/10/2026126.92 AUD
4/9/2026127.38 AUD
4/8/2026132.08 AUD
4/7/2026121.98 AUD
4/2/2026118.84 AUD
4/1/2026123.97 AUD
3/31/2026116.90 AUD
3/30/2026114.60 AUD
3/27/2026117.70 AUD
3/26/2026119.50 AUD
3/25/2026120.79 AUD
3/24/2026119.53 AUD
3/23/2026121.91 AUD
3/20/2026120.06 AUD
3/19/2026122.62 AUD
3/18/2026125.31 AUD
3/17/2026128.11 AUD
3/16/2026131.65 AUD
3/13/2026133.00 AUD
3/12/2026133.55 AUD
3/11/2026136.79 AUD
3/10/2026139.69 AUD
3/9/2026131.50 AUD
3/6/2026132.70 AUD
3/5/2026121.49 AUD
3/4/2026116.19 AUD
3/3/2026114.28 AUD
3/2/2026125.62 AUD
2/27/2026130.00 AUD
2/26/2026127.60 AUD
2/25/2026116.23 AUD
2/24/2026108.15 AUD
2/23/2026115.30 AUD
2/20/2026126.51 AUD
2/19/2026129.16 AUD
2/18/2026123.00 AUD
2/17/2026125.96 AUD
2/16/2026116.97 AUD
2/13/2026118.22 AUD
2/12/2026129.00 AUD
2/11/2026169.47 AUD
2/10/2026167.66 AUD
2/9/2026161.17 AUD
2/6/2026157.62 AUD
2/5/2026164.93 AUD
2/4/2026166.35 AUD
2/3/2026177.56 AUD
2/2/2026178.15 AUD
1/30/2026184.12 AUD
1/29/2026181.69 AUD
1/28/2026186.28 AUD
1/27/2026190.17 AUD
1/23/2026180.92 AUD
1/22/2026177.45 AUD
1/21/2026178.37 AUD
1/20/2026186.55 AUD
1/19/2026189.10 AUD
1/16/2026202.90 AUD
1/15/2026206.39 AUD
1/14/2026212.41 AUD
1/13/2026209.66 AUD
1/12/2026213.36 AUD
1/9/2026210.21 AUD
1/8/2026215.92 AUD
1/7/2026215.00 AUD
1/6/2026213.76 AUD
1/5/2026215.30 AUD
1/2/2026222.63 AUD
12/31/2025220.87 AUD
12/30/2025222.90 AUD
12/29/2025224.04 AUD
12/24/2025225.68 AUD
12/23/2025232.17 AUD
12/22/2025222.30 AUD
12/19/2025217.37 AUD
12/18/2025214.86 AUD
12/17/2025219.60 AUD
12/16/2025226.05 AUD
12/15/2025233.69 AUD
12/12/2025234.43 AUD
12/11/2025232.99 AUD
12/10/2025237.49 AUD
12/9/2025247.55 AUD
12/8/2025246.67 AUD
12/5/2025249.00 AUD
12/4/2025251.83 AUD
12/3/2025254.33 AUD
12/2/2025259.92 AUD
12/1/2025262.18 AUD
11/28/2025266.54 AUD
11/27/2025266.69 AUD
11/26/2025261.44 AUD
11/25/2025260.09 AUD
11/24/2025260.01 AUD
11/21/2025251.32 AUD
11/20/2025253.04 AUD
11/19/2025250.37 AUD
11/18/2025251.14 AUD
11/17/2025259.36 AUD
11/14/2025248.83 AUD
11/13/2025255.49 AUD
11/12/2025257.21 AUD
11/11/2025254.90 AUD
11/10/2025257.75 AUD
11/7/2025252.62 AUD
11/6/2025253.90 AUD
11/5/2025254.57 AUD
11/4/2025258.28 AUD
11/3/2025261.60 AUD
10/31/2025263.61 AUD
10/30/2025263.34 AUD
10/29/2025269.31 AUD
10/28/2025281.64 AUD
10/27/2025282.18 AUD
10/24/2025281.78 AUD
10/23/2025281.81 AUD
10/22/2025284.39 AUD
10/21/2025288.00 AUD
10/20/2025286.86 AUD
10/17/2025285.60 AUD
10/16/2025292.64 AUD
10/15/2025292.40 AUD
10/14/2025287.01 AUD
10/13/2025288.33 AUD
10/10/2025305.55 AUD
10/9/2025298.02 AUD
10/8/2025300.29 AUD
10/7/2025298.20 AUD
10/6/2025304.22 AUD
10/3/2025314.00 AUD
10/2/2025308.69 AUD
10/1/2025306.21 AUD
9/30/2025308.29 AUD
9/29/2025301.61 AUD
9/26/2025301.77 AUD
9/25/2025309.13 AUD
9/24/2025307.36 AUD
9/23/2025317.90 AUD
9/22/2025320.04 AUD
9/19/2025313.29 AUD
9/18/2025298.81 AUD
9/17/2025294.88 AUD
9/16/2025300.93 AUD
9/15/2025294.14 AUD
9/12/2025298.45 AUD
9/11/2025298.70 AUD
9/10/2025297.08 AUD
9/9/2025298.30 AUD
9/8/2025299.52 AUD
9/5/2025298.23 AUD
9/4/2025296.35 AUD
9/3/2025290.81 AUD
9/2/2025294.67 AUD
9/1/2025298.96 AUD
8/29/2025298.81 AUD
8/28/2025300.00 AUD
8/27/2025306.00 AUD
8/26/2025302.38 AUD
8/25/2025303.44 AUD
8/22/2025306.41 AUD
Access this data via the Eulerpool API
Get Free API Key

Pro Medicus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
127.33 M AUD
86.51 M AUD
60.65 M AUD
Jan 1, 2024
166.33 M AUD
117.62 M AUD
82.79 M AUD
Jan 1, 2025
220.54 M AUD
165.25 M AUD
115.22 M AUD
Jan 1, 2026 (e)
260.37 M AUD
215.73 M AUD
145.01 M AUD
Jan 1, 2027 (e)
338.54 M AUD
280.49 M AUD
196.15 M AUD
Jan 1, 2028 (e)
419.74 M AUD
347.77 M AUD
246.15 M AUD
Jan 1, 2029 (e)
522.51 M AUD
432.92 M AUD
288.80 M AUD
Jan 1, 2030 (e)
518.10 M AUD
429.26 M AUD
244.76 M AUD

Pro Medicus Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 6:00 PM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
DIV.AUD
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
27.0031.0033.0050.0056.0068.0094.00127.00166.00220.00260.00338.00419.00522.00518.00533.00
58.8214.816.4551.5212.0021.4338.2435.1130.7132.5318.1830.0023.9624.58-0.772.90
96.30100.00100.0096.00100.0098.5398.9499.21100.00100.00100.00100.00100.00100.00100.00100.00
26.0031.0033.0048.0056.0067.0093.00126.00166.00220.00260.00338.00419.00522.00518.00533.00
9.0014.0014.0025.0030.0042.0061.0086.00117.00165.00215.00280.00347.00432.00429.00–
33.3345.1642.4250.0053.5761.7664.8967.7270.4875.0082.6982.8482.8282.7682.82–
6.009.009.0019.0023.0030.0044.0060.0082.00115.00145.00196.00246.00288.00244.00263.00
100.0050.00–111.1121.0530.4346.6736.3636.6740.2426.0935.1725.5117.07-15.287.79
0.030.050.080.150.170.210.310.430.570.790.891.061.28–––
50.0066.6760.0087.5013.3323.5347.6238.7132.5638.6012.6619.1020.75–––
101.38104.12104.29104.43104.46104.59104.58104.59104.65104.66104.66104.66104.66104.66104.66104.66
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pro Medicus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pro Medicus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pro Medicus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pro Medicus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pro Medicus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pro Medicus stock margins

The Pro Medicus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pro Medicus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pro Medicus.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
99.28 %
62.64 %
45.32 %
Jan 1, 2022
99.51 %
65.84 %
47.22 %
Jan 1, 2023
99.57 %
67.94 %
47.63 %
Jan 1, 2024
99.82 %
70.71 %
49.78 %
Jan 1, 2025
99.86 %
74.93 %
52.24 %
Jan 1, 2026 (e)
99.86 %
82.85 %
55.69 %
Jan 1, 2027 (e)
99.86 %
82.85 %
57.94 %
Jan 1, 2028 (e)
99.86 %
82.85 %
58.64 %

Pro Medicus Stock Revenue, EBIT, Earnings per Share

The Pro Medicus earnings per share therefore indicates how much revenue Pro Medicus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.65 AUD
0.41 AUD
0.29 AUD
Jan 1, 2022
0.90 AUD
0.59 AUD
0.42 AUD
Jan 1, 2023
1.22 AUD
0.83 AUD
0.58 AUD
Jan 1, 2024
1.59 AUD
1.12 AUD
0.79 AUD
Jan 1, 2025
2.11 AUD
1.58 AUD
1.10 AUD
Jan 1, 2026 (e)
2.49 AUD
2.06 AUD
1.39 AUD
Jan 1, 2027 (e)
3.23 AUD
2.68 AUD
1.87 AUD
Jan 1, 2028 (e)
4.01 AUD
3.32 AUD
2.35 AUD

Pro Medicus business model & stock analysis

Pro Medicus Ltd. is an Australian company specializing in the development and distribution of medical imaging software solutions. The company was founded in 1983 and is headquartered in Melbourne.

Pro Medicus SWOT Analysis

Strengths

Pro Medicus Ltd has several key strengths:

  • Strong brand reputation and recognition in the healthcare industry.
  • Advanced and innovative technology solutions.
  • Robust financial performance and steady revenue growth.
  • Well-established partnerships and customer relationships.

Weaknesses

Pro Medicus Ltd also faces certain weaknesses:

  • Limited geographical presence and reliance on specific market segments.
  • Dependency on key clients for a significant portion of revenue.
  • Relatively small size compared to some major competitors.

Opportunities

Pro Medicus Ltd should consider the following opportunities:

  • Expanding into new markets and geographic regions.
  • Diversifying product offerings to cater to a wider range of healthcare professionals.
  • Capitalizing on the growing demand for telemedicine and remote healthcare solutions.
  • Forming strategic partnerships to enhance market reach and penetration.

Threats

Pro Medicus Ltd should be aware of potential threats:

  • Intense competition from larger and more established players in the industry.
  • Technological advancements and rapid changes in the healthcare landscape.
  • Regulatory and compliance challenges in different markets.
  • Economic fluctuations and uncertainties affecting healthcare budgets.

Pro Medicus Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Pro Medicus historical P/E ratio, EBIT multiple, and P/S ratio

Pro Medicus annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pro Medicus shares outstanding

The number of shares of Pro Medicus was 104.66 M in 2025. This indicates how many shares Pro Medicus is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
104.59 M Stocks
Jan 1, 2022
104.58 M Stocks
Jan 1, 2023
104.59 M Stocks
Jan 1, 2024
104.65 M Stocks
Jan 1, 2025
104.66 M Stocks
Jan 1, 2026 (e)
104.66 M Stocks
Jan 1, 2027 (e)
104.66 M Stocks
Jan 1, 2028 (e)
104.66 M Stocks

Pro Medicus Dividend History

26 years of dividend payments · 10 consecutive increases

YearAnnual DividendYoY ChangePayments
20260.46AUDYTD—1×
Feb 26, 20260.46AUD↑ 6.7%1/1
20250.79AUD↑ 37.5%2×
Feb 27, 20250.36AUD↑ 13.6%1/2
Sep 3, 20250.43AUD↑ 20.0%2/2
20240.57AUD↑ 33.3%2×
20230.43AUD↑ 36.4%2×
20220.31AUD↑ 46.7%2×
20210.21AUD↑ 25.0%2×
20200.17AUD↑ 14.3%2×
20190.15AUD↑ 78.6%3×
20180.08AUD↑ 65.6%2×
20170.05AUD↑ 69.0%2×

Pro Medicus dividend history and estimates

In 2025, Pro Medicus paid a dividend amounting to 0.79 AUD. Dividend means that Pro Medicus distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
0.21 AUD
0.00 AUD
0.00 AUD
Jan 1, 2022
0.31 AUD
0.00 AUD
0.00 AUD
Jan 1, 2023
0.43 AUD
0.00 AUD
0.00 AUD
Jan 1, 2024
0.57 AUD
0.00 AUD
0.00 AUD
Jan 1, 2025
0.79 AUD
0.00 AUD
0.00 AUD
Jan 1, 2026
0.89 AUD
0.00 AUD
0.00 AUD
Jan 1, 2027 (e)
0.00 AUD
1.06 AUD
0.00 AUD
Jan 1, 2028 (e)
0.00 AUD
1.28 AUD
0.00 AUD

Pro Medicus dividend payout ratio

In 2025, Pro Medicus had a payout ratio of 71.37%. The payout ratio indicates the percentage of the company's profits that Pro Medicus distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
72.64 %
Jan 1, 2022
73.95 %
Jan 1, 2023
73.90 %
Jan 1, 2024
72.23 %
Jan 1, 2025
71.37 %
Jan 1, 2026 (e)
63.93 %
Jan 1, 2027 (e)
56.71 %
Jan 1, 2028 (e)
54.23 %

Current Pro Medicus forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
25.00 %
Buy
64.71 % (11)
Hold
35.29 % (6)
Sell
0.00 % (0)
12M Price Target
244.80
Last Price
193.85
Currency
AUD
12M Return Potential
26.28 %
LTM Return
0 %

Pro Medicus Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/13/20240.37AUD-74.25 MAUD-2024 Q2
8/16/20230.30AUD-65.82 MAUD-2023 Q4
2/14/20230.26AUD-59.87 MAUD-2023 Q2
8/18/20220.21AUD-50.40 MAUD-2022 Q4
2/16/20220.19AUD-43.50 MAUD-2022 Q2
8/18/20210.18AUD-40.44 MAUD-2021 Q4
2/17/20210.15AUD-38.05 MAUD-2021 Q2
8/20/20200.11AUD-31.28 MAUD-2020 Q4
2/13/20200.11AUD-28.65 MAUD-2020 Q2
8/22/20190.08AUD-23.95 MAUD-2019 Q4

EESG©

Eulerpool ESG Scorecard© for the Pro Medicus stock

34/100
45
Environment
36
Social
23
Governance
E

Environment

20
Scope 1 - Direct Emissions1.9
Scope 2 - Indirect emissions from purchased energy118.9
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions120.9
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees26.7
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pro Medicus shareholder structure

% Name
23.11467%
Hupert (Sam Aaron)
Hupert (Sam Aaron)
23.07297%
Hall (Anthony Barry)
Hall (Anthony Barry)
1.71442%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.08086%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.92980%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
0.91935%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
...

Pro Medicus Beneficial Ownership Filings (SEC 13D/G)

Free Float
50.7%
Float Shares
-
Shares Outstanding
-

Pro Medicus Executives and Management Board

15 members · avg. age 69 · 33 % women

MW

Mr. Malte Westerhoff

General Manager Europe and Global Chief Technology Officer

1.59 M AUD

Management

SL

Mr. Sean Lambright

Global Head of Sales - Visage Imaging Inc

1.21 M AUD
SH

Dr. Sam Hupert

Chief Executive Officer, Managing Director, Executive Director · since 2010

965,221.00 AUD
CH

Mr. Clayton Hatch

Chief Financial Officer

500,773.00 AUD
DT

Mr. Danny Tauber

General Manager - Australia · since 2011

423,573.00 AUD
BL

Mr. Brad Levin

General Manager - North America and Global Head of Marketing

401,248.00 AUD
TG

Ms. Teresa Gschwind

Global Head - Customer Service

–

Board of Directors

AH

Mr. Anthony Hall

Technology Director, Executive Director

373,261.00 AUD
PK

Mr. Peter Kempen

Non-Executive Independent Chairman of the Board

250,000.00 AUD
LF

Dr. Leigh Farrell

Non-Executive Independent Director

125,000.00 AUD
AG

Mr. Anthony Glenning

Non-Executive Independent Director

125,000.00 AUD
DS

Ms. Deena Shiff (69)

Non-Executive Independent Director

125,000.00 AUD
AW

Ms. Alice Williams

Non-Executive Independent Director

125,000.00 AUD

Pro Medicus Supply Chain

Pro Medicus Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
5 companies
#Nameβ 1YTrend
1
Healius
Customer·Health Care Providers & Services·AU
0.59
0.83
0.79
0.89
0.83
0.95
—
2
JPMorgan Chase
Supplier·Customer·Banks·US
0.42
0.36
0.41
0.66
0.69
0.87
0.23
3
Citigroup
Supplier·Customer·Banks·US
0.88
0.26
0.22
0.31
0.61
0.72
0.27
4
Apple
Supplier·Customer·Technology Hardware, Storage & Peripherals·US
0.22
0.61
0.54
0.10
-0.48
0.67
-0.20
5
HSBC Holdings
Supplier·Customer·Banks·GB
0.18
0.44
0.05
-0.73
-0.75
0.45
-0.42

Frequently asked questions about Pro Medicus

The business model of Pro Medicus Ltd revolves around providing advanced healthcare imaging software solutions. The company specializes in developing and delivering a comprehensive range of radiology solutions that enhance workflow efficiency and improve patient care. Pro Medicus offers cutting-edge products like Visage AI, Visage 7, and Visage RIS, which allow healthcare professionals to efficiently manage and analyze medical images. By combining innovative technology with a customer-centric approach, Pro Medicus helps healthcare providers worldwide optimize their imaging operations and deliver accurate diagnoses. With its focus on developing state-of-the-art software solutions, Pro Medicus positions itself as a leader in the medical imaging industry.

Pro Medicus Ltd is primarily active in the healthcare industry.

The main competitors of Pro Medicus Ltd in the market include other medical imaging companies such as Carestream Health, Change Healthcare, and Sectra AB. These companies also specialize in providing medical imaging solutions and technology to healthcare providers and are prominent players in the industry. Pro Medicus Ltd competes with them in terms of product offerings, innovation, customer base, and market share.

Pro Medicus Ltd is a renowned healthcare imaging and information technology provider. Established in 1983, the company has a rich history of pioneering innovative solutions in the medical imaging industry. With a strong focus on radiology, Pro Medicus has developed advanced imaging software that improves efficiency and enhances patient care. The company's success is attributed to its commitment to research and development, resulting in cutting-edge technologies and multiple industry awards. Pro Medicus operates globally, serving prominent healthcare institutions and professionals. With its profound expertise and dedication to advancing medical imaging technology, Pro Medicus Ltd continues to lead the industry in providing innovative solutions for the healthcare sector.

Some significant milestones achieved by Pro Medicus Ltd include the successful expansion into major global markets, such as the United States and Europe, further solidifying its position as a leading provider of healthcare imaging solutions. The company has also experienced continuous revenue growth, achieving record-breaking financial results year after year. Pro Medicus Ltd has consistently developed and released innovative software solutions, enhancing efficiency and productivity for healthcare professionals. Additionally, the company has formed strategic partnerships with top-tier healthcare organizations, further establishing its reputation as a trusted industry leader. These accomplishments have propelled Pro Medicus Ltd's growth and success in the competitive healthcare technology sector.

Pro Medicus Ltd primarily operates in Australia and the United States.

Pro Medicus Ltd is a leading healthcare IT solutions provider with a strong commitment to excellence and innovation. The company's core values revolve around delivering exceptional products and services that empower healthcare professionals to enhance patient care and outcomes. Pro Medicus emphasizes a customer-centric approach and strives to provide customized solutions tailored to meet the unique needs of its clients. With a clear focus on technological advancements and high-quality imaging software, Pro Medicus constantly pushes the boundaries in the healthcare industry. By fostering a culture of collaboration and continuous improvement, Pro Medicus Ltd is dedicated to transforming the way medical images are managed and shared worldwide.

Analysts currently set an average price target of 226.59 AUD for the Pro Medicus stock (median: 244.80 AUD), implying +16.9 % versus the latest price. The consensus is based on 17 analyst ratings.

Pro Medicus Analyst Price Targets 2026

17 analysts currently rate the Pro Medicus stock: 13 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Pro Medicus to generate revenue of 260.37 M AUD and earnings per share of 1.39 AUD.

Pro Medicus Analyst Price Targets 2026

Converted at the current exchange rate, the Pro Medicus share trades at 121.13 EUR (198.85 AUD).

The Pro Medicus share (PME.AX) is listed on 3 stock exchanges, including: Frankfurt (PMC.F), ASX (PME.AX).

Pro Medicus Ltd is a global company specializing in providing advanced IT solutions for the healthcare industry. They offer innovative information and image management solutions that are used by leading healthcare organizations worldwide. Their main divisions include Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and Telemedicine. Their PACS solutions allow hospitals and healthcare organizations to store, manage, and share digital images from medical diagnostic devices such as CT, MRI, and X-ray machines. These solutions are scalable and provide high-quality image quality for radiologists and other specialists to make informed diagnoses. Their RIS is an integrated solution designed specifically for radiology departments and practices, providing complete patient and order management, as well as integrated workflow tools to improve the efficiency and accuracy of diagnosing and evaluating medical imaging data. Their telemedicine solutions enable radiology professionals to edit and share medical images remotely over the internet, particularly beneficial in facilities with limited resources or for quick access to medical images in emergency diagnoses. In addition, Pro Medicus Ltd also offers specialized solutions for clinical decision support, automated medical image analysis, and patient management. Their clinical decision support provides assistance to medical professionals in diagnosis and treatment monitoring, while the automated analysis of medical image data allows for the quick processing of large amounts of data, producing results that can be utilized by professionals for diagnostic purposes. Their patient management solutions provide comprehensive capture and management of health data that can be used by doctors and other professionals to develop better treatment options for their patients. Pro Medicus Ltd is a global company with a strong focus on research and development. They have partnerships with leading healthcare organizations worldwide and possess a strong portfolio of intellectual property. Their business model is based on the sale of products and services specifically designed for the needs of the healthcare industry. The company emphasizes innovation, customer satisfaction, and delivering high-quality solutions that are scalable and flexible for various users. Overall, Pro Medicus Ltd is an innovative market leader in the field of medical IT solutions. They are globally recognized for their products and services and are expected to continue playing a significant role in the healthcare industry.

The expected revenue of Pro Medicus is 260.37 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pro Medicus is 145.01 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pro Medicus is currently 143.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pro Medicus stock.

The price-to-sales ratio (P/S) of Pro Medicus is currently 79.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pro Medicus stock.

The Eulerpool Quality Score for Pro Medicus is 8/10.

The ISIN of Pro Medicus is AU000000PME8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pro Medicus is 591723. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pro Medicus is PME.AX. The ticker symbol is used to trade Pro Medicus shares on the stock exchange.

Over the past 12 months, Pro Medicus paid a dividend of 0.79 AUD . This corresponds to a dividend yield of about 0.40 %. For the coming 12 months, Pro Medicus is expected to pay a dividend of 1.06 AUD.

The current dividend yield of Pro Medicus is 0.40 %.

Pro Medicus pays a dividend, distributed in the months of , , , .

Pro Medicus paid dividends every year for the past 14 years.

For the upcoming 12 months, dividends amounting to 1.06 AUD are expected. This corresponds to a dividend yield of 0.53 %.

Pro Medicus is assigned to the 'Health' sector.

To receive the latest dividend of Pro Medicus from amounting to 0.46 AUD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Pro Medicus distributed 0.5 AUD as dividends.

The dividends of Pro Medicus are distributed in AUD.

All fundamentals and in-depth analysis of Pro Medicus

Our stock analysis for Pro Medicus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pro Medicus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pro Medicus Stock
Pro Medicus Revenue→
Pro Medicus Stock
Pro Medicus Net Income→
Pro Medicus Stock
Pro Medicus P/E→
Pro Medicus Stock
Pro Medicus P/S→
Pro Medicus Stock
Pro Medicus EBIT→
Pro Medicus Stock
Pro Medicus Dividend→
Pro Medicus Stock
Pro Medicus Directors Dealings→
Pro Medicus Stock
Pro Medicus Stocks→
Pro Medicus Stock
Pro Medicus Market capitalization→
Pro Medicus Stock
Pro Medicus Debt→
Pro Medicus Stock
Pro Medicus Liabilities→
Pro Medicus Stock
Pro Medicus Equity→
Pro Medicus Stock
Pro Medicus AAQS→
Pro Medicus Stock
Pro Medicus Employees→
Pro Medicus Stock
Pro Medicus ROE→
Pro Medicus Stock
Pro Medicus ROA→
Pro Medicus Stock
Pro Medicus ROCE→
Pro Medicus Stock
Pro Medicus News→
Pro Medicus Stock
Pro Medicus Analyst Price Targets→

Health Stocks

Pro-DexPrivia Health GroupProbiotix HealthPrivate Rented SectorProcept BioroboticsPRISM BioLab CoProcessa PharmaceuticalsPrincipal Capital PCLProcter & Gamble HealthPrince Pharmaceutical CoProcyonPrime MedicineAll Stocks A–Z →